Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35063
Conference/Presentation Title: | IgD myeloma: A unique subtype with unclear prognostic significance. | Authors: | Low M. ;Grigoriadis G. ;Vilcassim S.;Fedele P. ;Shaw B. | Institution: | (Shaw, Fedele, Vilcassim, Grigoriadis, Low) Monash Health (Vilcassim, Low) Monash University, Clayton, Australia | Presentation/Conference Date: | 9-Oct-2020 | Copyright year: | 2020 | Publisher: | Blackwell Publishing Ltd | Publication information: | British Journal of Haematology. Conference: 60th Annual Scientific Meeting of the British Society for Haematology. Birmingham United Kingdom. 189 (Supplement 1) (pp 247), 2020. Date of Publication: April 2020. | Abstract: | Aim: IgD myeloma is a rare plasma cell dyscrasia which is traditionally reported to have a poor outcome compared to patients with other types of M protein. This is thought to be due to higher rates of renal failure, chemotherapy resistance and a more aggressive clinical course. Recent studies have reported conflicting evidence into the survival outcomes of patients with IgD myeloma (Wang GR, Sun WJ et al. 2016, Chen L, Fan F et al. 2019). We therefore aimed to analyse the presentation and prognosis of IgD myeloma in a local cohort of patients in the era of novel therapies. Method(s): Eight patients with an IgD M protein were identified from Monash Medical Centre, Victoria, based on serum electrophoresis records in patients between 2013 and 2018. Retrospective data were collected in regards to M-protein type and size, biochemical and bone marrow analysis at presentation, renal function, co-morbidities and treatment received. Result(s): Median age at diagnosis was 75.5 years of age (range 51-83 years old). 50% presented with anaemia and 75% presented with renal failure with one patient requiring dialysis. The majority had high serum-free light chains at diagnosis with 87.5% having affected light chain above 1000 mg/l. All patients had ISS stage 3, 62.5% had R-ISS stage 3 disease at diagnosis. A single patient had smouldering myeloma without a myeloma defining event after 24 months of observation. Of the remaining patients, 85% received bortezomibbased induction, and 15% received thalidomide-based induction. Only one patient proceeded to autologous transplant. Overall survival in IgD myeloma patients was not statistically different from non-IgD myeloma patients (median 40 vs. 53 months; P = 0.332). Conclusion(s): IgD myeloma remains a rare plasma cell dyscrasia and presents commonly with high serum-free light chains, renal disease and anaemia. In our cohort, survival did not appear worse than non-IgD myeloma patients. | Conference Start Date: | 2020-04-27 | Conference End Date: | 2020-04-29 | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/bjh.16638 | ISSN: | 1365-2141 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/35063 | Type: | Conference Abstract | Type of Clinical Study or Trial: | Observational study (cohort, case-control, cross sectional or survey) |
Appears in Collections: | Conferences |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.